Confirming the identity and purity of a candidate pharmaceutical is critical to effectively screening chemical libraries that contain vast types of small molecules across a range of biological targets. Chemists need to be sure they have synthesized the expected compound. In this high-throughput screening environment, the ability to obtain information in multiple MS and UV detection modes – in a single injection – is invaluable.
LC/MS analysis helps you excludes false positives and maintain high product quality, but can be time-consuming in moving a drug through the discovery process. Achieving high sample throughput is key to moving compounds from hit to lead status.
- The ACQUITY UPLC® System’s sub-2 µm LC particle technology generates high-efficiency and fast separations ideal for screening activities.
- The scan speed of the ACQUITY® SQD provides better characterization of narrow chromatographic peaks.
- Waters software allows you to quickly and automatically process data and generate a summary report.
Combining fast analysis with open-access software delivers the power of LC/MS to chemists who are not analytical instrumentation specialists. A single complete system enables them thoroughly screen a compound, from sample introduction to end results. It allows them to quickly and easily know what they’ve made, and allows the experts to work on the difficult analytical problems.
The use of the fast-scanning MS along with the throughput of the ACQUITY UPLC System’s remote status monitoring software allows chemists to obtain high-quality comprehensive data about their compounds in the shortest possible timeframes. This, combined with intelligent open access software, allows you to make informed decisions faster, and better support the needs of the modern drug discovery process.
